A Multicenter, Open Label Study Of Oral Revlimid And Prednisone (Rp) Followed By Oral Revlimid Melphalan And Prednisone (Mpr) In Newly Diagnosed Elderly Multiple Myeloma Patients.
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 03 Aug 2017
At a glance
- Drugs Lenalidomide (Primary) ; Melphalan (Primary) ; Prednisone (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions; Therapeutic Use
- 31 Jul 2017 Planned End Date changed from 1 Aug 2017 to 1 Aug 2019.
- 05 Feb 2016 Planned End Date changed from 1 Aug 2013 to 1 Aug 2017 as reported by ClinicalTrials.gov.
- 24 Mar 2012 Planned number of patients 46 added as reported by European Clinical Trials Database.